Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment

Biomarker Research

Volumn 2, Issue 1, 2014, Pages

  Abdi, Jahangir ^a,b   Qiu, Lugui ^c   Chang, Hong ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Bone marrow stroma; CAMDR; miRNA; Multiple myeloma

Indexed keywords

BORTEZOMIB; HISTONE DEACETYLASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 135B; MICRORNA 15A; MICRORNA 15A 5P; MICRORNA 16; MICRORNA 16 5P; MICRORNA 199A; MICRORNA 199A 5P; MICRORNA 21; MICRORNA 24 3P; MICRORNA 548M; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BONE MARROW STROMA CELL; CELL ADHESION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFER; DOWN REGULATION; DRUG RESPONSE; DRUG TARGETING; EPIGENETICS; EXOSOME; GENE EXPRESSION; HUMAN; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; ONCOGENE C MYC; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84922216332     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-2-10     Document Type: Review

References (41)

1. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012, 2012:157496. 3471001, 23093834.
2. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121:2975-2987. 10.1182/blood-2012-08-448548, 3624943, 23321256.
3. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 2013, 27:464-472. 10.1038/leu.2012.213, 22828443.
4. Vallet S, Podar K. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma. Expert Opin Biol Ther 2013, 13(Suppl 1):S35-53.
5. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008, 105:12885-12890. 10.1073/pnas.0806202105, 2529070, 18728182.
6. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013, 12:2331-2341. 10.1158/1535-7163.MCT-12-1166, 24030633.
7. Jianxiang Chi EB, Xiao-He C, Rajko K, Steve T, Deborah H, Daniela T, Saunders TL NJ, Francesco P, Jacqueline B, Wainscoat JS, Lawrie CSHCH. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 2011, 6:1-17. 10.1186/1745-6150-6-1, 3043529, 21199581.
8. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010, 18:367-381. 10.1016/j.ccr.2010.09.005, 3561766, 20951946.
9. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009, 114:e20-26. 10.1182/blood-2009-08-237495, 19846888.
10. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009, 113:6669-6680. 10.1182/blood-2009-01-198408, 2710922, 19401561.
11. Campo S, Allegra A, D'Ascola A, Alonci A, Scuruchi M, Russo S, Avenoso A, Gerace D, Campo GM, Musolino C. MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma. Br J Haematol 2014, doi:10.1111/bjh.12828.
12. Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012, 118:878-887. 10.1002/cncr.26297, 21837684.
13. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 2013, 13(1):S125-137.
14. Munker R, Liu CG, Taccioli C, Alder H, Heerema N. MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol 2010, 123:201-204. 10.1159/000302889, 2881892, 20357429.
15. Ballabio E, Armesto M, Breeze CE, Manterola L, Arestin M, Tramonti D, Hatton CS, Lawrie CH. Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?. Blood Cancer J 2012, 2:e83. 10.1038/bcj.2012.31, 3432485, 22922378.
16. Wong KY, Huang X, Chim CS. DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis 2012, 33:1629-1638. 10.1093/carcin/bgs212, 22715154.
17. Chesi M, Bergsagel PL. Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma. Cancer Cell 2010, 18:299-300. 10.1016/j.ccr.2010.10.004, 20951939.
18. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013, 19:2096-2106. 10.1158/1078-0432.CCR-12-3325, 23446999.
19. Soon P, Kiaris H. MicroRNAs in the tumour microenvironment: big role for small players. Endocr Relat Cancer 2013, 20:R257-267. 10.1530/ERC-13-0119, 23878074.
20. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69:1009-1015. 2680075, 19155309.
21. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950-1961. 10.1038/sj.leu.2402295, 11753617.
22. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598. 10.1038/nrc2189, 17646864.
23. Ell B, Kang Y. MicroRNAs as regulators of tumor-associated stromal cells. Oncotarget 2013, 4:2166-2167. 3926815, 24293477.
24. Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 2014, 24:153-160. 10.1016/j.tcb.2013.09.007, 24125906.
25. Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011, 25:145-152. 10.1038/leu.2010.230, 3083119, 20966935.
26. Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, Bradner JE, Dalton WS, Sotomayor E, Tao J. A microenvironment-mediated c-Myc/miR-548 m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013, 123:4612-4626. 10.1172/JCI64210, 3809771, 24216476.
27. Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011, 52:1991-1998. 10.3109/10428194.2011.591004, 21718132.
28. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H, Qiu L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma 2011, 52:1787-1794. 10.3109/10428194.2011.576791, 21534877.
29. Corthals SL, Jongen-Lavrencic M, De Knegt Y, Peeters JK, Beverloo HB, Lokhorst HM, Sonneveld P. Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res 2010, 34:677-681. 10.1016/j.leukres.2009.10.026, 20031211.
30. Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grander D, Corcoran MM. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 2009, 315:2941-2952. 10.1016/j.yexcr.2009.07.001, 19591824.
31. Rimma Berenstein BIW, Axel N, Marlies W, Antonio P, Bernd D, Olga B. Aberrant expression of miRNA and mRNA of cell cycle and adhesion-related genes in bone marrow stroma cells derived from patients with multiple myelom. Blood 2013, 122:3149. 10.1182/blood-2013-01-474916, 24002445.
32. Lavinia Raimondi NA, Maria Teresa Di M, Emanuela A, Marzia Leotta DC, Annamaria G, Antonino Neri S, Taverna PDA, Riccardo A, Antonio Giordano P, Tassone TP. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget 2014, 5.
33. Reagan YM MR, Yong Z, Patricia M, Salomon M, Yu-Tzu T, Priya D, Zhi Ning L, Masoumeh M, Antonio S, Yosra A, Susanna S, John R, Kaplan DL, Roccaro AM, Ghobrial IM. Microrna-dependent modulation of osteogenesis in a 3D in vitro bone marrow model system of multiple myeloma. Blood 2013, 122:3093. 10.1182/blood-2013-09-525451, 24178960.
34. Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One 2013, 8:e79752. 10.1371/journal.pone.0079752, 3819242, 24223191.
35. Hao M, Zhang L, An G, Sui W, Yu Z, Zou D, Xu Y, Chang H, Qiu L. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol 2011, 4:37. 10.1186/1756-8722-4-37, 3189173, 21936961.
36. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013, 123:1542-1555. 10.1172/JCI66517, 3613927, 23454749.
37. Hannafon BN, Ding WQ. Intercellular Communication by Exosome-Derived microRNAs in Cancer. Int J Mol Sci 2013, 14:14240-14269. 10.3390/ijms140714240, 3742242, 23839094.
38. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526. 10.1158/1078-0432.CCR-07-2223, 18451212.
39. Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol 2009, 2:649-662. 10.1586/ehm.09.55, 21082957.
40. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674. 10.1038/nrc2714, 19693095.
41. Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006, 20:333-342. 10.1016/j.blre.2005.08.003, 16920238.